Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916640 | 0.91 | ITGB3 (0.48) | PSMB5ITGB3ITGA2BGRIA1ACACB | |
| SCHEMBL24276152 | 0.90 | MMP1 (0.48) | PSMB5ITGB3ITGA2B | |
| SCHEMBL24916575 | 0.90 | PSMB5 (0.43) | PSMB5ITGB3ITGA2BGRIA1ACACB | |
| SCHEMBL24942160 | 0.88 | PSMB5 (0.41) | PSMB5ITGB3ITGA2BGRIA1ACACB | |
| SCHEMBL24916562 | 0.85 | ITGB3 (0.41) | PSMB5ITGB3ITGA2BGRIA1PTPN1 | |
| SCHEMBL24276200 | 0.82 | ITGB1 (0.45) | PSMB5ITGB3ITGA2BGRIA1 | |
| SCHEMBL24276160 | 0.80 | ITGB3 (0.43) | PSMB5ITGB3ITGA2BGRIA1ACACB | |
| SCHEMBL24276204 | 0.80 | ITGB3 (0.56) | PSMB5ITGB3ITGA2BGRIA1ACACB | |
| SCHEMBL24916583 | 0.79 | ACACB (0.61) | ITGB3ITGA2BACACB | |
| Fosgonimeton SCHEMBL23425642 | 0.75 | SRC (0.51) | GRIA1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215377-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215376-A1 | METHODS OF TREATING NEUROPATHIES | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023163971-A1 | METHODS OF TREATING COVID-RELATED DISORDERS | ATHIRA PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023004393-A1 | METHODS OF TREATING PARKINSON'S DISEASE AND/OR LEWY BODY DISEASE OR DISORDER(S) | ATHIRA PHARMA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023287556-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ATHIRA PHARMA, INC. (US) | 2023-01-19 | — | — | WO | disclosed |